combretastatin A-4 phosphate
Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide
... agent combretastatin A-4 phosphate (CA-4-P) has been quantified in two types of murine tumour, the breast adenocarcinoma CaNT and the round cell sarcoma ...
6
Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate
... Our study represents the first study of CA4P for an oph- thalmic disease in humans. Clinical experience with CA4P consists of 18 completed and ongoing clinical trials in on- cology and ophthalmology, together comprising ...
10
Evaluation of Sydnone-Based Analogs of Combretastatin A-4 Phosphate (CA4P) as Vascular Disrupting Agents for Use in Cancer Therapy
... Abstract: The combretastatins have attracted significant interest as small molecule therapies for cancer due to their ability to function as vascular disrupting agents. We have successfully prepared a range of ...
11
SYNTHESIS AND BIOLOGICAL EVALUATION OF CYCLOPROPANE DERIVATIVE OF COMBRETASTATIN CA-4-PHOSPHATE
... A-4 phosphate (CA-4-P), a tubulin- depolymerizing agent structurally related to colchicines, is in clinical trials as a vascular disrupting .... Combretastatin A-4 was originally ...
8
Sequential Systemic Administrations of Combretastatin A4 Phosphate and Radioiodinated Hypericin Exert Synergistic Targeted Theranostic Effects with Prolonged Survival on SCID Mice Carrying Bifocal Tumor Xenografts
... was found a few orders of magnitude higher than that of a monoclonal antibody (mAb) with a lengthy local retention over 3 weeks relative to 3 days with mAbs [16]. Consequently, the cumulative radiation dose in the tumor ...
11
“Combretastatin A-4 and its Analogs in Cancer Therapy” by Sonia Arora, Andres F. Gonzalez, Khushbu Solanki, United States of America.
... CA-4, although a potent anti-vascular agent, binds to plasma proteins in the blood thereby reducing its cellular permeability reducing the amount of drug found at the target site and decreasing its effect. Due to ...
7
Synthesis and evaluation of azetidinone analogues of combretastatin A 4 as tubulin targeting agents
... compound which had been pre-prepared as stock solutions in ethanol to furnish the concentration range of study, 1 nM–100 µM, and re-incubated for a further 72 h. Control wells contained the equivalent volume of the ...
65
Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen Combretastatin and Cyclofenil Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
... Competitive binding affinity experiments were carried out using purified baculovirus-expressed human ER α and ER β and fluoromone, a fluorescein labelled estrogen ligand. ER binding ability of the selected compounds was ...
50
Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4.
... compound, combretastatin A-4 (CA4), was shown to be effective at causing selective tumor vascular collapse, within minutes, at non-toxic ...sodium phosphate salt prodrug, disodium ...
55
<p>Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects</p>
... CA4P/GA LPs (1 mL) suspension was transferred into the dialysis bag (cutoff 3.5 kDa), and the bag was placed into a conical bottle containing 50 mL release solution. The system was kept in a shaking incubator (THZ-82; ...
16
Synthesis and biological evaluation of Combretastatin A-4 derivatives containing a 3’-O-substituted carbonic ether moiety as potential antitumor agents
... CA-4 phosphate (CA-4P, Figure 1), was identified and progressed into clinical trials as a potential vascular disrupting agent that could be used in combi- nation with conventional cytotoxic therapies for ...
8
Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial cadherin signaling
... Figure 4, A [arrowheads] and B), which has been previously shown to be the hallmark of VE-cadherin disengagement ...Figure 4, A [arrowheads] and B), leading to the formation of separated gaps (Figure 4A, ...
16
An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate
... Colchicine-related microtubule depolymerizing agents are the largest family of low MW drugs to have tumour vascular disrupting activity at relatively non-toxic doses (Tozer et al., 2005; Kanthou and Tozer, 2007; Siemann, ...
13
An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate
... and 4 h after administration and can remain lowered in both animal and human tumours for up to 24 h before vasculature re-establishes itself (Dark et ...generation combretastatin, combretastatin A-1 ...
12
Haemoxygenase in tumours and its role in vascular targeting with combretastatin a4 phosphate
... Despite the fact that NAC was effective at reversing the increase in HO-1 protein levels induced by CA-4-P, under these conditions, it only partially blocked the increase in overall HO enzyme activity. Therefore, ...
241
Phosphate removal from aqueous solutions using polyaniline/ Ni0.5Zn0.5Fe2O4 magnetic nanocomposite
... O 4 composite was prepared by precipitating PANI on the surface of pre- synthesized Ni ...O 4 at room temperature ...O 4 /PANI nanocomposite was magnetically separated, washed with ...
7
Diphenyl 2 (α,α,4 trichlorobenzyl)phenyl phosphate
... a solution of phenol (12.7 g, 0.135 mol) in benzene (70 ml) was added dropwise with stirring to a solution of ,,4-trichloro--phenyl-o-tolyl dichlorophosphinate (27.3 g, 0.0675 mol) and dried redistilled 2,4,6- ...
7
Media optimization for inorganic phosphate solubilizing bacteria isolated from anand argiculture soil
... Phosphorous is second only to nitrogen as an essential macronutrient for plant growth and development (Schefferet al., 1998). Soil is rich in insoluble mineral and organic phosphates but deficient in available ...
11
Synthesis and crystal structure of 4 fluorobenzylammonium dihydrogen phosphate, [FC6H4CH2NH3]H2PO4
... hydrogen phosphate unit to an adjacent one, which results in the formation of an infinite two-dimensional corrugated layer of anions extending parallel to the ab plane ...
8
A study on Hypophosphatemia in critically ill patients in ICU its incidence and predictors in Thanjavur Medical College Hospital
... requires phosphate ions to make adenosine triphosphate. This phosphate is obtained from circulating inorganic phosphate stores, which are readily diffusible across the cell ...serum phosphate ...
119